When will the ARISTOSPAN patents expire, and when will generic ARISTOSPAN be available?

Sponsor	Phase
University of Florida	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ethypharm	ARISTOSPAN	triamcinolone hexacetonide	INJECTABLE;INJECTION	016466-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ethypharm	ARISTOSPAN	triamcinolone hexacetonide	INJECTABLE;INJECTION	016466-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 24, 2026

Executive summary: Aristospan, a brand of triamcinolone acetonide (long-acting corticosteroid injectable), sits in a mature anti-inflammatory market with limited near-term growth upside tied to (1) geography and channel mix, (2) price erosion versus generics and authorized generics, (3) competitive intensity from other depot steroids, and (4) exposure to product supply stability and payer formulary controls. Financial trajectory is dominated by declining brand volume in markets where generics are entrenched, with any remaining premium linked to managed-care contracting, milestone-driven procurement by large distributors, and use-case consolidation in musculoskeletal and allergic/inflammatory indications.

What is Aristospan’s revenue model and how does the drug make money?

Short answer: Aristospan’s revenue tracks units of depot corticosteroid injections sold multiplied by net price (wholesale acquisition cost less rebates, chargebacks, and distributor margins). In practice, net price is the swing factor once generic substitutions spread.

Revenue mechanics that matter for Aristospan

Unit volume is the primary demand signal. Depot steroid use is seasonal in some allergic settings and steady in chronic musculoskeletal care.
Net price follows payer and channel pressure. Once competing generics or therapeutically equivalent products establish formulary positions, Aristospan’s net price compresses faster than wholesale list prices.
Channel structure influences realizations. Large-account hospital and ambulatory networks often negotiate deeper discounts for commonly used depot steroids.
Supply continuity affects sell-through. Depot injectables are sensitive to manufacturing disruptions; lost allocation can create short-term revenue dips and longer-term formulary switching.

What usually drives pharmacy and clinic pull-through

Clinical familiarity and substitution reluctance. Long-acting steroids have comparable pharmacology, but prescribers may show brand loyalty for handling, perceived efficacy, or patient response history.
Tender and group purchasing organization (GPO) contracts. These can lock in a preferred depot steroid for a defined period.
Billing patterns. Injectable reimbursement can be influenced by local coding and payer administration rules, affecting effective demand even when clinical need remains stable.

How does Aristospan’s market size and growth rate compare with other depot corticosteroids?

Short answer: Aristospan competes in a crowded field of generic triamcinolone acetonide and alternative long-acting steroid depots. The category is mature, so growth typically comes from population needs and care pathway changes, not from new-to-market innovation.

Competitive set and substitution pressure

Same-active or closely aligned depot steroid products are the core substitutes. Substitution tends to increase when:
- Multiple AB-rated products gain coverage,
- Hospital formularies standardize to one or two depot steroids,
- Supply disruptions shift allocation toward competitors.
Brand premium narrows over time through contracting and pharmacy substitution.

Where incremental growth can still come from

Indication mix shifts: musculoskeletal injections and inflammatory management tend to hold share when payer coverage is stable.
Facility procurement consolidation: brand choice becomes “sticky” when a facility standardizes.
Territorial brand protection: some geographies maintain branded packaging or specific presentations longer than others, extending premium pricing.

What patents protect Aristospan and how strong is the patent estate?

Short answer: The practical patent question for Aristospan is usually less about “new drug” exclusivity and more about product-specific protections such as formulation, manufacturing process, device-related features, or method-of-use. The patent estate strength is judged by whether those protections extend beyond the active ingredient’s baseline expiry.

Patent estate structure that typically governs depot steroid brands

Active ingredient coverage: for legacy corticosteroids, active ingredient patents are often long expired.
Formulation patents: protect concentration, suspension behavior, stabilizers, particle size distribution, or sterilization strategy.
Manufacturing method patents: protect specific process parameters for suspension consistency and shelf life.
Packaging/presentation patents: protect container closure systems or filling methods for injectables.
Use/payer claims: method-of-use claims exist in some products but are frequently narrower and easier to design around.

Litigation and enforcement posture

Depot steroid products commonly face generic entry through “same drug, same route” approaches rather than complex reformulation.
If the estate contains only legacy active ingredient claims, enforcement has limited impact on modern generic substitution because the main AB substitution pathways do not require design-around.

Result for investors and licensors: For Aristospan, financial resilience is more sensitive to contracting and supply than to an aggressive, enforceable patent wall, unless a credible formulation or manufacturing patent remains in force in key markets.

When does Aristospan lose exclusivity or face key expiry milestones?

Short answer: Aristospan’s exclusivity is usually driven by a mix of (1) legacy active ingredient patent expiry, (2) any remaining formulation or process patents, and (3) data exclusivity or marketing exclusivity in specific jurisdictions if applicable.

Exclusivity timeline mechanics to model

US: exclusivity effects are primarily mediated by Orange Book-listed patents and related litigation. If no unexpired listed patents cover the commercialized product, generic entry can accelerate.
EU and UK: exclusivity is tied to marketing authorization and any data protection periods, followed by patent life for formulation/process.
Other markets: brand premium persists where regulatory listings and local patent coverage remain active.

What tends to happen after the last listed patent expires

Net price compression. Generic and authorized generic uptake drives discounting.
Hospital and clinic standardization. Procurement committees switch to the lowest net-cost AB option.
Brand volume decline. Brand market share falls as substitution becomes routine.

What is the Orange Book status of Aristospan and which patents are listed for generic challengers?

Short answer: Orange Book status determines whether generic filers can launch immediately on label at entry and whether a Paragraph IV strategy is feasible. The key question is which patents (if any) are listed for the specific formulation, strength, and dosage form.

How to interpret Orange Book risk for Aristospan-style products

If only expired patents are listed for the relevant strength/presentation, the generic entry timeline is governed by regulatory approval timing rather than patent litigation.
If there are unexpired patents covering a specific presentation, a generic challenger may seek:
- Paragraph IV certification (invalidity or non-infringement),
- Design-around at the formulation or manufacturing step.
Litigation affects the entry date and can delay revenue erosion, but only when a meaningful unexpired patent is in the Orange Book for the marketed product.

Commercial takeaway: Revenue trajectory should be modeled on the probability and impact of AB-entry accelerating after the last listed patent expires or after litigation settlement.

Do Paragraph IV challenges or generic entry risks exist for Aristospan?

Short answer: The generic entry risk depends on whether unexpired, listed patents still cover the marketed presentation and whether generic filers can certify safely. For many older depot steroids, the practical risk is high because active ingredient coverage is often stale.

Key entry risk pathways

Direct AB substitution where the product is not protected by unexpired listed patents tied to the commercial formulation.
Authorized generic strategy by an incumbent or licensee, which can preserve short-term market stability but still compresses net price.
Design-around via formulation/process changes if formulation patents exist and are still enforceable.

How to model post-entry financial impact

Net revenue decline often precedes full unit loss due to rebate and contract renegotiation.
Share loss tends to be rapid in hospital procurement settings where formularies update quickly.
Price erosion can stabilize after initial entry waves, as contracting settles into a new baseline.

What patent litigation or settlements could affect Aristospan’s revenue trajectory?

Short answer: Litigation is only financially material if it blocks or delays generic entry for the marketed presentation. For mature depot steroid brands, litigation matters less when the last listed patents are weak or already expired.

Settlement patterns that change the financial curve

Consent judgments or “carve-out” settlements that preserve brand supply or maintain a preferred contract can slow volume erosion.
Narrow injunctions tied to a specific strength or presentation can create partial revenue protection.
Early resolution settlements can reduce expected litigation-driven delay, moving revenue erosion closer to regulatory timelines.

Investor lens: Track settlement terms that specify launch dates, whether a partial launch triggers substitution elsewhere, and whether the brand remains non-interchangeable in formulary.

What formulation and manufacturing patents could block “same drug” competitors?

Short answer: For depot injectables, the highest protection value usually comes from formulation and manufacturing method patents that preserve suspension characteristics, stability, sterilization approach, and shelf life.

Typical formulation levers in depot steroids

Suspension particle behavior: uniformity and resuspendability.
Stabilizers and excipients: binders and surfactants that maintain dispersion.
Sterilization and filtration method: influences impurity profile and shelf-life performance.
Fill-finish process controls: viscosity and fill volume tolerances.

Manufacturing and quality systems as de facto barriers

Even when patents expire, competitors can face:

Process validation complexity
Quality system scaling
Lot-to-lot consistency requirements that delay launch timing or raise compliance risk

Commercial impact: delays from manufacturing/quality issues can create short windows of revenue lift, but they do not generally restore long-term premium pricing once AB competition is established.

How does Aristospan’s FDA regulatory status shape market access and competition?

Short answer: FDA status affects market access through labeling, approval basis, and substitution equivalence rather than through clinical superiority in a mature steroid category.

Regulatory levers that affect revenue

Approval and labeling stability: stable labeling supports substitution.
Reference product continuity: if the brand is the reference, it can retain some pull-through in certain settings.
Distribution and supply: FDA manufacturing site status and recall history can temporarily shift demand.

Risk from labeling and coding changes

Even without clinical differentiation, changes in billing rules or administration coding can shift demand to competing depots.

How does Aristospan compare with competing drugs in the same class?

Short answer: Depot steroids are clinically substitutable in many workflows, so competitive outcomes hinge on net price, contracting, and perceived reliability rather than differentiated mechanism.

Comparison dimensions that drive market outcomes

Acquisition cost after rebates
Formulary placement
Availability and lead times
Perceived patient response consistency
Injection handling and administration workflow

What “winning” usually means in this market

Sustaining preferred formulary status
Maintaining distribution allocations during supply constraints
Keeping net price competitive through contracting

Where are the main revenue exposures for Aristospan: geography, channel, and payer mix?

Short answer: Revenue is exposed to geographic variability in patent coverage, formulary behavior, and generic penetration intensity. Channel exposure is heavily influenced by whether the brand is sold primarily through hospitals, ambulatory clinics, or specialty distributors.

Geography: what to model

Mature generic markets: rapid net price compression and share decline.
Markets with slower substitution: brand persists longer, supported by local procurement behavior.
Local regulatory pathways: can change generic entry timing independently from US/EU dynamics.

Channel: where substitution happens fastest

Hospital systems and large clinic networks update formularies quickly.
Independent practices may be slower, especially when prescribers anchor to brand history.

What commercial scenarios determine Aristospan’s next 1–3 years financial trajectory?

Short answer: The next phase is primarily a contracting and competitive timing exercise. Three scenarios usually bracket outcomes.

Scenario 1: No new generic acceleration

Revenue decline slows to category-level erosion.
Net price remains pressured but stable through contracting.
Unit volume declines continue gradually.

Scenario 2: Entry wave increases AB substitution

Net price compresses faster.
Share shifts quickly in institutional settings.
Revenue drop becomes front-loaded.

Scenario 3: Supply or quality disruption shifts allocation

Temporary revenue spike if allocation constraints favor the brand.
Longer-term risk if competitors capture formulary share during disruption.

Key Takeaways

Aristospan’s financial trajectory is driven by net price compression and unit-share erosion typical of mature depot steroid products once AB-equivalent competition strengthens.
Patent and Orange Book status determine whether entry is delayed, but for older actives the strongest levers are usually formulation/process protections tied to the specific marketed presentation.
Commercial outcomes depend most on formulary contracting, channel mix (hospital vs ambulatory), and supply continuity.
Short-term revenue changes often reflect competitive entry timing and contract renegotiations, not new clinical differentiation.

FAQs

How does depot steroid substitution typically impact net pricing for branded products like Aristospan?
What is the usual impact of hospital formulary standardization on brand retention for AB-equivalent injectable steroids?
Which patent types for long-acting injectables most affect generic entry timing: formulation, manufacturing process, or method-of-use?
How can supply disruptions temporarily change the market share outcome for depot steroid brands?
What indicators best predict whether an Aristospan label will face faster AB competition in a given geography?

References (APA)

No sources cited.

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	44
Clinical Trials:	1
Patent Applications:	4,535
DailyMed Link:	ARISTOSPAN at DailyMed

AI Deep Research

Questions you can ask:

Summary for ARISTOSPAN

Recent Clinical Trials for ARISTOSPAN